Jul. 8, 2019—A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.
Jul. 2, 2019—Joel Hardman, PhD, an internationally recognized scientist and educator who chaired the Department of Pharmacology at Vanderbilt University School of Medicine from 1975 to 1990, died June 30, 2019 in Hoosick Falls, New York, after a lengthy illness. He was 85.
Jul. 1, 2019—Babies born after being exposed to both opioids and benzodiazepines before birth are more likely to have severe drug withdrawal, requiring medications like morphine for treatment, compared to infants exposed to opioids alone.
Jun. 26, 2019—Biomarkers of DNA methylation, which regulate gene expression, can be a predictor of breast cancer risk.
Jun. 26, 2019—Cataracts are uncommon in babies but when they occur the cloudy lenses must be removed without delay or blindness may result.
Jun. 20, 2019—The ABIM Foundation has awarded the 2019 John A. Benson Jr., MD Professionalism Article Prize to five scholarly articles — one commentary and four research pieces — that explore physician burnout, unprofessional behavior and integrity in research.
Jun. 18, 2019—A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work
Jun. 13, 2019—More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in the Journal of Clinical Oncology.
Jun. 13, 2019—Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, is joining Vanderbilt-Ingram Cancer Center (VICC).
Jun. 13, 2019—Armed with $1.2 million in funding from the National Heart, Lung and Blood Institute (NHLBI), researchers at Vanderbilt University Medical Center are searching to understand the cause of a rare airway disease in hopes of developing better treatments.
Jun. 13, 2019—The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.
Jun. 6, 2019—VUMC has joined an international effort to streamline and accelerate development of vaccines and other treatments against a growing worldwide surge of deadly and debilitating viral infections.